Drugs and patents in ATC class B01AE - Direct thrombin inhibitors

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
ARGATROBAN	argatroban
ARGATROBAN IN 0.9% SODIUM CHLORIDE	argatroban
ARGATROBAN IN SODIUM CHLORIDE	argatroban
>Tradename	>Generic Name

Last updated: June 14, 2026

Market dynamics and patent landscape for ATC Class B01AE (direct thrombin inhibitors)

Direct thrombin inhibitors (DTIs) in ATC Class B01AE drive a largely mature market shaped by (1) patent expirations across pivotal small molecules (notably dabigatran etexilate) and (2) the downstream patent strategy for fixed-dose combinations, line extensions, and manufacturing/process improvements. Commercially, the class is dominated by dabigatran-based anticoagulation in atrial fibrillation and VTE indications, with market access increasingly determined by generic entry pathways and the risk profile from patent estates and exclusivity (including data exclusivity where applicable). Remaining DTI pipeline activity is thinner than in earlier cycles, so the legal and regulatory battleground concentrates on “evergreening” patents and Orange Book listings linked to specific strengths and dosage forms rather than new active ingredients.

Where the patent estate matters most for B01AE

Core active-ingredient patents: first-generation molecule patents and early formulation/process claims.
Product and method-of-use patents: dosing regimens, patient subsets, and label-linked methods.
Dosage form and manufacturing patents: granulation, pellet/particle engineering, coating/film systems, polymorph/solid-state control, and scale-up.
Combination and line extensions: co-packaged or multi-strength product strategies, plus stability/biowaiver-linked changes where supported.
Horizon of exclusivity vs. patent expiration: exclusivity can extend market protection beyond the last core patent even after generic-ready patent expiry, depending on jurisdiction and FDA approval history.

Which direct thrombin inhibitors are in ATC B01AE and who holds the key patents?

Answer: ATC Class B01AE is concentrated around small-molecule DTIs, with dabigatran etexilate as the dominant marketed agent. The patent landscape is therefore heavily associated with the dabigatran etexilate originator’s family (molecule, salts/solid-state, manufacturing, and product-specific claims) plus any later product-formulation and method-of-use extensions.

Key marketed DTIs typically treated as B01AE

Dabigatran etexilate (oral DTI prodrug; active dabigatran)
Other direct thrombin inhibitors: class-level mapping varies by jurisdiction and coding practices, but dabigatran remains the core anchor for patent and market dynamics given its scale and longest commercial runway.

Patent holders that usually control B01AE market exclusivity

Originators of dabigatran etexilate (and successor entities through assignment).
Sponsors holding formulation/process patents tied to specific capsule strengths and manufacturing lines.
Smaller life sciences entities rarely dominate this class; control tends to sit with the original DTI developer and its IP-operating partners.

What patents protect dabigatran etexilate (ATC B01AE) and how is the estate structured?

Answer: Dabigatran etexilate protection typically clusters into (1) compound/salt coverage, (2) formulation and solid-state control, (3) manufacturing/process steps, and (4) method-of-use tied to clinical endpoints and labeled dosing.

How dabigatran etexilate patent estates are usually layered

1) Active compound and prodrug/salt chemistry

Claims cover the chemical entity, protected salts, and prodrug forms used to enable oral bioavailability.
These are the core patents that set the “hard stop” for generic substitution.

2) Formulation patents

Multi-component capsule composition and excipient systems.
Solid-state form control, including particle size distribution and polymorph management.
Coating or protective layers designed to manage conversion and stability.

3) Manufacturing/process patents

Granulation and pelletization approaches.
Milling, mixing, and drying process windows.
Scale-up parameters affecting dissolution and bioavailability.

4) Method-of-use patents

Dosing schedules and patient stratification aligned to labeled indications (atrial fibrillation stroke prevention, DVT/PE treatment and prophylaxis).
Clinically oriented claims may remain even when composition patents weaken.

Where litigation usually concentrates

Orange Book listing tied to the exact strength (mg), dosage form (capsules), and manufacturing site (controlled process claims).
Patents asserting bioequivalence-relevant constraints (particle engineering, dissolution profile targets) are common hot spots.

When does ATC B01AE lose exclusivity and what are the practical expiry drivers?

Answer: For B01AE, market exclusivity loss is driven by the combination of last relevant composition/process patent expiry plus any remaining exclusivity (data and market exclusivity regimes where applicable) that delays approval or commercial launch even if a generic can file.

Practical drivers by timeline (generic readiness)

Patent expiry: the earliest date a generic can potentially launch if no blocking patents remain in force for the listed product.
Paragraph IV timing (US): whether a generic challenger's ANDA triggers litigation with an automatic stay (when applicable).
Regulatory exclusivity: can block approval even after some patents expire.
Settlement agreements: can extend launch dates beyond statutory limits.

Which patents cause Paragraph IV challenges for direct thrombin inhibitors?

Answer: For dabigatran etexilate-like DTI estates, Paragraph IV challenges typically target formulation and manufacturing patents listed in the Orange Book for the relevant strength and dosage form. Suiting focuses on claims that remain after core compound expiration, plus method-of-use claims where label alignment is contestable.

Common claim types attacked in generic challenges

Composition claims tied to excipient systems or protective layers.
Solid-state form and polymorph-specific manufacturing.
Process claims that are translated into generic process equivalence arguments.
Method-of-use claims tied to labeled dosing regimens.

Litigation risk profile

Generic challengers often accept risk on method-of-use but fight composition/process claims that are technically harder to prove and more dependent on manufacturing details.
Originators emphasize product-by-product infringement (capsule strength-specific).

What is the Orange Book status of dabigatran and other B01AE DTIs?

Answer: The Orange Book status is product- and strength-specific. For the dominant DTI (dabigatran etexilate), the Orange Book listing typically includes a mix of patents claiming active ingredient, dosage form, and formulation/method-of-use.

Orange Book mapping that matters for market access

List patents by:
- Drug product (strength, dosage form).
- Active ingredient (and whether the generic lists the same salt form).
- Patent categories (composition, method-of-use, or manufacturing).
Identify which listed patents are most likely to be asserted for infringement at launch.

How strong is the patent estate for ATC B01AE, and where are the weak links?

Answer: The patent estate strength in B01AE is strongest where originators have dense, product-linked formulation/manufacturing claims that are difficult for generics to design around. Weak links emerge when:

Method-of-use claims are narrow and not tightly aligned to label-by-label dosing.
Manufacturing claims are drafted with process steps that can be re-engineered.
Some patents are expiring earlier than adjacent formulation/process patents, creating a staggered relaxation of protection.

Strength is also a function of “engineering distance”

If generic developers can design around solid-state/formulation claims by using alternative particle engineering and dissolution profiles that still meet bioequivalence, they reduce infringement probability.
If originators enforce broad equivalents or if patents are tied to reproducible physical properties, design-around becomes harder.

What formulation patents protect direct thrombin inhibitors and do they block generics?

Answer: Formulation patents for oral DTIs frequently claim:

Capsule composition and protective excipient systems.
Solid-state form and particle engineering parameters affecting in vivo performance.
Stability and dissolution behavior windows.

These patents can block generics at the relevant strength because FDA requires bioequivalence, and originators can assert that meeting the spec inherently practices protected formulation/manufacturing features.

Dosage form constraints that elevate infringement risk

Multi-layer or protective compositions.
Narrow particle size distributions tied to dissolution kinetics.
Manufacturing steps that originators claim as necessary for meeting the required dissolution profile.

How do method-of-use patents affect DOAC competition in B01AE?

Answer: Method-of-use patents can extend exclusivity by tying claims to clinically meaningful regimens. In practice, their enforceability and relevance depend on whether generic labeling and prescribing could induce infringement.

Method-of-use enforceability vectors

Label-driven claims: if the generics’ FDA-approved labeling mirrors the patented method, infringement risk rises.
Narrow patient subsets: claims limited to specific risk profiles may reduce infringement if labeling differs.
Litigation posture: originators often use method-of-use claims as leverage even when composition claims are harder to prove in generic process cases.

What generic entry risks exist for dabigatran and other B01AE DTIs?

Answer: Generic entry risk is dominated by:

Whether any Orange Book patents remain enforceable for the relevant strength/dosage form.
The probability of settlement-driven launch delays after Paragraph IV.
Design-around feasibility for formulation and manufacturing claims.
The strength of originator infringement theories tied to process or product properties.

Commercial entry scenarios

Scenario A: Patent clearing: generic can launch immediately upon expiry with clean non-infringement position or successful challenge.
Scenario B: Launch delayed by settlement: generic entry date is pushed beyond the earliest technical entry window.
Scenario C: Design-around failure: formulation/process changes do not avoid infringement, leading to injunction or loss in litigation.

What biosimilar risk applies to ATC B01AE direct thrombin inhibitors?

Answer: Biosimilar risk is low to none for small-molecule DTIs in B01AE because biosimilar pathways apply to biologicals, not small-molecule generics. Market protection is therefore dominated by small-molecule patent and exclusivity structures rather than biosimilar patent frameworks.

How does B01AE compare with other oral anticoagulant classes on patent durability?

Answer: Across anticoagulants, patent durability depends on how many “secondary” product patents originators secured beyond active ingredient. In practice:

DTIs like dabigatran often show dense formulation/process IP tied to capsule performance.
Factor Xa inhibitors also show similar patterns, but competitive intensity and label evolution can alter which patents remain commercially relevant at any given time.

Competitive landscape implication

When multiple anticoagulants compete for the same indications, patent settlements and switching economics can determine uptake even after generic entry.

What patent litigation affects B01AE market pricing and launch dates?

Answer: The main market impacts come from:

Injunction threats tied to remaining Orange Book patents.
Automatic stay mechanisms after Paragraph IV filings (US).
Settlement agreements that set negotiated launch dates and product entry terms.

How litigation translates into market dynamics

Delay in launch preserves originator pricing power and market share.
Successful generic entry increases price competition and compresses margins across the class.

What licensing deals and settlement agreements influence generic launches for B01AE?

Answer: In B01AE, the practical effect of licensing and settlements is to determine generic launch dates and sometimes scope (specific strengths, specific indications, or product line coverage). For dabigatran-containing markets, the originator’s ability to leverage formulation/process patents and Orange Book listings typically drives settlements rather than fully litigated outcomes through trial.

Regulatory status: how do FDA approval pathways interact with B01AE patent timing?

Answer: For small-molecule DTIs, FDA pathways are primarily ANDA-based for generics, with approval tied to:

Patent certifications (and litigation outcomes).
Whether blocking patents are resolved.
Whether exclusivity or other regulatory restrictions persist.

Key regulatory timing mechanics

ANDA submission timing does not equal launch timing.
Launch is constrained by:
- unresolved patents,
- court outcomes,
- statutory exclusivity,
- and settlements.

Which companies are positioned to challenge B01AE patents and launch generics?

Answer: Generic entry in B01AE is usually contested by established generic manufacturers and specialty generics that pursue Paragraph IV challenges and negotiated settlements. The winners are those that can:

Clear the strongest product-specific Orange Book patents,
Demonstrate formulation/process non-infringement or prevailing legal defenses,
Offer competitive pricing quickly once launch is permitted.

Competitive selection criteria

ANDA readiness for each strength.
Manufacturing capability aligned to bioequivalence targets.
Litigation capacity and settlement leverage.

Where is revenue exposure highest in B01AE and how does it map to patent risk?

Answer: Revenue exposure concentrates in the dominant DTI (dabigatran etexilate) and its label-linked indications. Patent risk for revenue concentrates on:

the next in-scope strength(s) for generic entry,
and any remaining formulation/process or method-of-use patents that can block “at-launch” competition.

Actionable revenue-patent mapping

Build a strength-by-strength matrix:
- Orange Book patents per strength,
- earliest expiry date,
- expected generic entry scenario (A/B/C above),
- likely settlement-driven delay.

Key patent estate takeaways for B01AE market strategy

The class is dominated by small-molecule DTI protection, not biosimilar dynamics.
Dabigatran etexilate’s patent estate is the primary driver of market access and generic timing.
Formulation and manufacturing patents create the most durable barriers because they tie to reproducible product performance and capsule-level product identity.
Method-of-use patents add leverage when label alignment makes generic prescribing plausibly infringing.
Market dynamics are determined by strength-specific Orange Book listings, Paragraph IV litigation posture, and settlements that convert legal uncertainty into predictable launch calendars.

Key Takeaways

ATC B01AE direct thrombin inhibitors are primarily small-molecule drugs; generic entry and pricing are driven by patent and regulatory timing rather than biosimilar frameworks.
Dabigatran etexilate is the central commercial and patent reference point; its estate typically stacks compound, formulation, solid-state, manufacturing, and method-of-use protections.
Formulation and manufacturing patents are the most common launch blockers because they are product- and strength-specific and harder to design around.
The practical exclusivity horizon equals the last enforceable Orange Book patent for each strength plus any regulatory exclusivity and litigation or settlement delays.
For market strategy, the essential work is strength-by-strength patent mapping and scenario modeling around Paragraph IV outcomes.

FAQs

1) Which dabigatran etexilate patents most often block generic ANDA launches for specific capsule strengths?
Orange Book-listed formulation, solid-state, and manufacturing patents tied to the capsule strength are the typical blockers.

2) How do settlements in DTI patent cases affect the earliest possible generic market entry date?
Settlements often replace litigation uncertainty with negotiated launch dates, delaying entry beyond earliest legal expiry windows.

3) Do method-of-use patents for DTIs still matter after active-ingredient patent expiry?
Yes, if claims are label-aligned and remain enforceable; they can still constrain launch or trigger litigation leverage.

4) What manufacturing changes can reduce infringement risk for formulation/process patents in B01AE?
Alternative solid-state control, particle engineering, and process parameter sets that avoid claimed process steps or protected product properties are used, subject to bioequivalence.

5) Is there any biosimilar competition risk for B01AE direct thrombin inhibitors?
No, because B01AE direct thrombin inhibitors are small molecules, not biologicals.

References (APA)

U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
European Medicines Agency. (n.d.). European public assessment reports and EPAR product information databases. EMA.